361 related articles for article (PubMed ID: 9935250)
1. Pharmacokinetics and metabolism of single oral doses of trovafloxacin.
Vincent J; Teng R; Dalvie DK; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):8S-13S. PubMed ID: 9935250
[TBL] [Abstract][Full Text] [Related]
2. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers.
Melnik G; Schwesinger WH; Teng R; Dogolo LC; Vincent J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):424-6. PubMed ID: 9758286
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
Dalvie DK; Khosla NB; Navetta KA; Brighty KE
Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858
[TBL] [Abstract][Full Text] [Related]
4. Excretion and metabolism of trovafloxacin in humans.
Dalvie DK; Khosla N; Vincent J
Drug Metab Dispos; 1997 Apr; 25(4):423-7. PubMed ID: 9107540
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin.
Vincent J; Venitz J; Teng R; Baris BA; Willavize SA; Polzer RJ; Friedman HL
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():75-80. PubMed ID: 9222074
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys.
Teng R; Girard D; Gootz TD; Foulds G; Liston TE
Antimicrob Agents Chemother; 1996 Mar; 40(3):561-6. PubMed ID: 8851571
[TBL] [Abstract][Full Text] [Related]
7. Penetration of trovafloxacin into gynecologic tissues.
Martens MG; Maccato M; Van Hook C; Vincent J
Am J Surg; 1998 Dec; 176(6A Suppl):18S-22S. PubMed ID: 9935252
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects.
Vincent J; Hunt T; Teng R; Robarge L; Willavize SA; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):32S-38S. PubMed ID: 9935255
[TBL] [Abstract][Full Text] [Related]
9. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
Teng R; Liston TE; Harris SC
J Antimicrob Chemother; 1996 May; 37(5):955-63. PubMed ID: 8737145
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
Darwish M; Nunez R; Youakim JM; Robertson P
Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
Teng R; Harris SC; Nix DE; Schentag JJ; Foulds G; Liston TE
J Antimicrob Chemother; 1995 Aug; 36(2):385-94. PubMed ID: 8522468
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of intravenous-to-oral treatment and single-dose intravenous or oral prophylaxis with trovafloxacin.
Williams DJ; Hopkins S
Am J Surg; 1998 Dec; 176(6A Suppl):74S-79S. PubMed ID: 9935261
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
Wise R; Mortiboy D; Child J; Andrews JM
Antimicrob Agents Chemother; 1996 Jan; 40(1):47-9. PubMed ID: 8787877
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery.
Melnik G; Schwesinger WH; Dogolo LC; Teng R; Vincent J
Am J Surg; 1998 Dec; 176(6A Suppl):14S-17S. PubMed ID: 9935251
[TBL] [Abstract][Full Text] [Related]
15. Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.
Vincent J; Dogolo L; Baris BA; Willavize SA; Teng R
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):427-30. PubMed ID: 9758287
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics of trovafloxacin: its clinical significance].
Clara LO; Biglia MA
Medicina (B Aires); 1999; 59 Suppl 1():17-22. PubMed ID: 10436550
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of trovafloxacin with and without food in healthy volunteers.
Teng R; Dogolo LC; Willavize SA; Friedman HL; Vincent J
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():87-92. PubMed ID: 9222076
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of a fluoronaphthyridone, trovafloxacin (CP 99,219), in infants and children following administration of a single intravenous dose of alatrofloxacin.
Bradley JS; Kearns GL; Reed MD; Capparelli EV; Vincent J
Antimicrob Agents Chemother; 2000 May; 44(5):1195-9. PubMed ID: 10770751
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography.
Fischman AJ; Babich JW; Bonab AA; Alpert NM; Vincent J; Callahan RJ; Correia JA; Rubin RH
Antimicrob Agents Chemother; 1998 Aug; 42(8):2048-54. PubMed ID: 9687405
[TBL] [Abstract][Full Text] [Related]
20. The bioavailability of nasogastric versus tablet-form oral trovafloxacin in healthy subjects.
Vincent J; Teng R; Pelletier SM; Willavize SA; Friedman HL
Am J Surg; 1998 Dec; 176(6A Suppl):23S-26S. PubMed ID: 9935253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
